Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alcohol + cannabis
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
A combination of two commonly used substances that produces enhanced depressant effects on the central nervous system. When consumed together, alcohol increases the absorption of THC (tetrahydrocannabinol), the main psychoactive component in cannabis, leading to intensified effects. This combination affects areas of the brain responsible for memory, thinking, coordination, judgment, and sensory perception.
- Other names
- crossfadingpolyconsumptionpolysubstance use
02
Targets
CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on alcohol + cannabis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alcohol + cannabis.